We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.
ARTICLE · 22 APRIL 2016
Medac's 'Second Medical Use' Metoject PEN Patent Found Invalid

Gowling WLG
Contributor

Gowling WLG
The firm The firm’s lawyers speak English, French, Russian and Ukrainian. The firm’s client base...
View firm profileMedac's patent to methotrexate for subcutaneous administration for the treatment of inflammatory autoimmune diseases (including rheumatoid arthritis (RA)), has been found invalid.
CanadaIntellectual Property





